Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 4, 2011, Pages 759-764

  Sheu, Wayne H H ^a   Chuang, Hsiu Chun ^b   Cheng, Shiu Min ^c   Lee, Maw Rong ^d   Chou, Chi Chi ^d   Cheng, Fu Chou ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Glucose; Ischemia; Liquid chromatography mass spectrometry mass spectrometry; Microdialysis; Rosiglitazone

Indexed keywords

GLUCOSE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROL GROUP; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG PENETRATION; GERBIL; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; HALF LIFE TIME; HYPOGLYCEMIA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; PARAMETER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STROKE;

ANIMALS; AUTOMATION, LABORATORY; BLOOD GLUCOSE; BRAIN; BRAIN INFARCTION; BRAIN ISCHEMIA; GERBILLINAE; GLUCOSE; HALF-LIFE; HYPOGLYCEMIC AGENTS; LIMIT OF DETECTION; MALE; MICRODIALYSIS; PPAR GAMMA; RANDOM ALLOCATION; REPERFUSION INJURY; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES; TISSUE DISTRIBUTION;

EID: 78650236128     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.10.008     Document Type: Article

References (30)

1. Sundararajan S., Landreth G.E. Antiinflammatory properties of PPARgamma agonists following ischemia. Drug News Perspect. 2004, 17:229-236.
2. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999, 354:141-148.
3. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995, 270:12953-12956.
4. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996, 45:1661-1669.
5. Wang C.X., Ding X., Noor R., Pegg C., He C., Shuaib A. Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J. Cereb. Blood Flow Metab. 2009, 29:1683-1694.
6. Raji A., Seely E.W., Bekins S.A., Williams G.H., Simonson D.C. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003, 26:172-178.
7. Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J. Neurochem. 2006, 97:435-448.
8. Malinowski J.M., Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin. Ther. 2000, 22:1151-1168. discussion 1149-1150.
9. Rao M.N., Mullangi R., Katneni K., Ravikanth B., Babu A.P., Rani U.P., Naidu M.U., Srinivas N.R., Rajagopalan R. Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. J. Clin. Pharmacol. 2002, 42:670-675.
10. Le Quellec A., Dupin S., Tufenkji A.E., Genissel P., Houin G. Microdialysis: an alternative for in vitro and in vivo protein binding studies. Pharm. Res. 1994, 11:835-838.
11. Johansen M.J., Newman R.A., Madden T. The use of microdialysis in pharmacokinetics and pharmacodynamics. Pharmacotherapy 1997, 17:464-481.
12. Cheng F.C., Wang J., Yang D.Y. A dual-probe microdialysis study in simultaneously monitoring extracellular pyruvate, lactate, and biogenic amines in gerbil striata during unilateral cerebral ischemia. Neurochem. Res. 2000, 25:1089-1094.
13. Chou C.C., Lee M.R., Cheng F.C., Yang D.Y. Solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry for determination of trace rosiglitazone in urine. J. Chromatogr. A 2005, 1097:74-83.
14. Cheng S.M., Yang L.L., Chen S.H., Hsu M.H., Chen I.J., Cheng F.C. Magnesium sulfate enhances exercise performance and manipulates dynamic changes in peripheral glucose utilization. Eur. J. Appl. Physiol. 2009, 108:363-369.
15. Bederson J.B., Pitts L.H., Germano S.M., Nishimura M.C., Davis R.L., Bartkowski H.M. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986, 17:1304-1308.
16. Davies M.I. A review of microdialysis sampling for pharmacokinetic applications. Anal. Chim. Acta 1999, 379:227-249.
17. Festuccia W.T., Oztezcan S., Laplante M., Berthiaume M., Michel C., Dohgu S., Denis R.G., Brito M.N., Brito N.A., Miller D.S., Banks W.A., Bartness T.J., Richard D., Deshaies Y. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 2008, 149:2121-2130.
18. Lau A.H., Lam N.P., Piscitelli S.C., Wilkes L., Danziger L.H. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin. Pharmacokinet. 1992, 23:328-364.
19. Fitzner Toft M., Petersen M.H., Dragsted N., Hansen A.K. The impact of different blood sampling methods on laboratory rats under different types of anaesthesia. Lab Anim. 2006, 40:261-274.
20. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
21. Stallones R.A., Dyken M.L., Fang H.C.H. Report of the Joint Committee for Stroke Facilities. I. Epidemiology for stroke facilities planning. Stroke 1972, 3:359-371.
22. Stegmayr B., Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia 1995, 38:1061-1068.
23. Lehto S., Ronnemaa T., Pyorala K., Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996, 27:63-68.
24. Bruno A., Kent T.A., Coull B.M., Shankar R.R., Saha C., Becker K.J., Kissela B.M., Williams L.S. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke 2008, 39:384-389.
25. Katsura K., Ekholm A., Asplund B., Siesjo B.K. Extracellular pH in the brain during ischemia: relationship to the severity of lactic acidosis. J. Cereb. Blood Flow Metab. 1991, 11:597-599.
26. Lindsberg P.J., Roine R.O. Hyperglycemia in acute stroke. Stroke 2004, 35:363-364.
27. LeMay D.R., Gehua L., Zelenock G.B., D'Alecy L.G. Insulin administration protects neurologic function in cerebral ischemia in rats. Stroke 1988, 19:1411-1419.
28. Voll C.L., Auer R.N. Postischemic seizures and necrotizing ischemic brain damage: neuroprotective effect of postischemic diazepam and insulin. Neurology 1991, 41:423-428.
29. Shuaib A., Ijaz M.S., Waqar T., Voll C., Kanthan R., Miyashita H., Liu L. Insulin elevates hippocampal GABA levels during ischemia. This is independent of its hypoglycemic effect. Neuroscience 1995, 67:809-814.
30. Kielian T., Drew P.D. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J. Neurosci. Res. 2003, 71:315-325.